

## Synthesis of 5(6)-dihydro-OSW-1 by using the intact skeleton of tigogenin

Li-Jun Chen,<sup>a</sup> Qi-Hai Xu,<sup>b</sup> Hao Huang,<sup>b</sup> Jing-Rong Lin<sup>a</sup> and Wei-Sheng Tian<sup>a,b,\*</sup>

<sup>a</sup>The Laboratory of Resource Chemistry, Shanghai Normal University, 100 Guilin Road, Shanghai 200234, PR China

<sup>b</sup>Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 354 Fenglin Road, Shanghai 200032, PR China

Received 16 January 2007; revised 26 January 2007; accepted 1 March 2007

Available online 3 March 2007

**Abstract**—5(6)-Dihydro-OSW-1 (**1**), an analogue of OSW-1 with the potent anticancer activity, was synthesized by utilizing the intact skeleton of tigogenin in 13 steps in 9.0% overall yield. This synthesis demonstrated an effective and reasonable synthetic strategy for bioactive steroids with side chains as compared with their routine synthesis.

© 2007 Elsevier Ltd. All rights reserved.

OSW-1 and its analogues were isolated from *Ornithogalum saundersiae* bulbs.<sup>1</sup> They are members of the cholestane glycoside family characterized by the attachment of a disaccharide to the C-16 position of the steroid aglycone. Their IC<sub>50</sub> values against human leukemia HL-60 cells range from 0.1 nM to 0.3 nM.<sup>2</sup> OSW-1, the main constituent of the bulbs, exhibits extraordinary cytostatic activities against various human malignant tumor cells. Its anticancer activities are 10–100 times more potent than some of the well-known anticancer agents currently in clinical use, such as mitomycin C, adriamycin, cisplatin, camptothecin, and taxol, but its toxicity to normal human pulmonary cells is significantly lower (IC<sub>50</sub> 1500 nM). Recently, Yu and co-workers reported that 5(6)-dihydro-OSW-1 (**1**) (Fig. 1) with simplified and easy prepared structure was slightly more potent than OSW-1 against the tested three cancer cell lines [including AGS (stomach cancer

cells) IC<sub>50</sub> 0.71 μM, 7404 (liver carcinoma cells) IC<sub>50</sub> 0.025 μM, and MCF-7 (breast cancer cells) 0.029 μM].<sup>3</sup>

The routine synthesis for OSW-1 and its analogues is starting from dehydroepiandrosterone.<sup>3,4</sup> It was prepared through the degradation of diosgenin, the procedure including thermal fragmentation in acetic acid at 200 °C, chromic oxide induced oxidation, elimination, oximation, and rearrangement.<sup>5</sup> As one part of our projects on the study of rational utilization of resource compounds,<sup>6</sup> we wish exploring a new synthesis of 5(6)-dihydro-OSW-1 (**1**) directly from tigogenin rather than the degraded product of diosgenin, epiandrosterone. Different from the reported synthesis of 5(6)-dihydro-OSW-1, the basic skeleton, 27-carbon atoms and functional groups of starting material tigogenin were fully, rationally utilized in our new synthetic strategy of 5(6)-dihydro-OSW-1 aglycon (Scheme 1).





Figure 1. The structures of OSW-1 and 5(6)-dihydro-OSW-1.

\* Corresponding author. E-mail: wstian@mail.sioc.ac.cn




Scheme 1.

Comparing the structure of 5(6)-dihydro-OSW-1 with the E/F ring-opened product of tigogenin, it is easy to find that both have similar side chains and the same disposal of the C-16 hydroxyl and the 21-methyl groups. To synthesize the aglycon of 5(6)-dihydro-OSW-1 (**1**) starting from the E/F ring-opened product of tigogenin directly, one only needs to introduce a hydroxyl group at C-17 in the latter (Scheme 1). Obviously, it is a rea-

sonable synthetic strategy according to the principle of atom economy in the organic synthesis.<sup>7</sup>

According to our synthetic plan shown in Scheme 2, tigogenin (**2**), an abundant and cheap steroidal sapogenin isolated from industrial waste, was readily acetylated with Ac<sub>2</sub>O in the presence of pyridine to afford the C-3 acetate of tigogenin in 99% yield. Tigogenin acetate **3** underwent regioselective oxone<sup>®</sup> oxidation of C-16 to produce **4** in 90% yield.<sup>6d,e</sup> The reaction of **4** with HOAc/HBr in CH<sub>2</sub>Cl<sub>2</sub> afforded the E/F ring-opened brominated product **5** in 89% yield.<sup>8</sup> The reduction of **5** with Zn and NH<sub>4</sub>Cl in refluxing ethanol gave the key intermediate **6** in 93% yield.

Subsequently, **6** underwent regioselectively thioketalization to afford C-16 mono-thioketal **7**.<sup>9</sup> 16-Thioketal **7** reacted with Ac<sub>2</sub>O in the presence of 70% HClO<sub>4</sub> to produce 16(17)-alkene **8** through a thioketal-opening-acetylation (TOA reaction).<sup>6d,e</sup> Desulfurization of **8** with W-2 Raney nickel at room temperature afforded compound **9**. Unlike their 5(6)-dehydro analogues, compound **8** and **9** were sensitive to the epimerization at



**Scheme 2.** Reagents and conditions: (a) Ac<sub>2</sub>O, Py, 45 °C, 99%; (b) oxone<sup>®</sup>, NaHCO<sub>3</sub>, buffer, H<sub>2</sub>O/acetone, 90%; (c) HBr/HOAc (30%), CH<sub>2</sub>Cl<sub>2</sub>, rt, 89%; (d) Zn, NH<sub>4</sub>Cl, EtOH, 93%; (e) HSCH<sub>2</sub>CH<sub>2</sub>SH, BF<sub>3</sub>·OEt<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 99%; (f) Ac<sub>2</sub>O, HClO<sub>4</sub> (0.01 equiv), CH<sub>2</sub>Cl<sub>2</sub>, 65%; (g) W-2 Raney Ni, EtOH, rt, 99%; (h) HOCH<sub>2</sub>CH<sub>2</sub>OH, HC(OEt)<sub>3</sub>, BF<sub>3</sub>·OEt<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 81%; (i) recrystallize, 67%; (j) K<sub>2</sub>CO<sub>3</sub>, MeOH; (k) TBSCl, imid., DMAP, CH<sub>2</sub>Cl<sub>2</sub>, 99% for two steps; (l) OsO<sub>4</sub>, Py, ether, -78 °C to rt, 10 h, then H<sub>2</sub>S bubbled through, 58%; (m) Swern oxidation, 88%; (n) LAH, THF, -78 °C, 70%; (o) 4 Å MS, **16**, then TMSOTf (0.05 equiv), -20 °C, CH<sub>2</sub>Cl<sub>2</sub>, 80%; (p) AcOH/ H<sub>2</sub>O (v/v, 3:1), 70 °C, 60%.

C20,<sup>6d</sup> so we got a mixture of 21 $\alpha$ -methyl and 21 $\beta$ -methyl steroids. The mixture appears a single point on thin layer chromatography and is inseparable. The C-22 carbonyl group of **9** was protected by ethylene glycol ketal<sup>6d,10</sup> to give 20-epimers. Fortunately, the two isomers of **10** could be separated by simple recrystallization. We performed similar transformations according to the literature,<sup>3,6d</sup> that is, conversion of 3-OAc in **10** to 3-OTBS in **11**, dihydroxylation of the 16,17-alkene function in **11** with OsO<sub>4</sub>, Swern oxidation of the 16 $\alpha$ -OH group in **12**, and stereoselective reduction of the 16-keto group in **13** to the 16 $\beta$ -OH group in **14**. Thus, the protected aglycone of 5(6)-dihydro-OSW-1 was synthesized with 13 steps in 9.0% overall yield. The glycosylation of aglycone **13** with disaccharide trichloroacetimidate **16**<sup>11</sup> in the presence of TMSOTf provided the corresponding protected 5(6)-dihydro-OSW-1 **15** in 80% yield. Removal of all of the protecting groups in AcOH/H<sub>2</sub>O (v/v = 3:1) at 70 °C afforded the desired 5(6)-dihydro-OSW-1 (**1**) in 60.2% yield. Its spectral data are identical with that of reported in the literature.<sup>3,12</sup>

#### References and notes

- Kubo, S.; Mimaki, Y.; Terao, M.; Sashida, Y.; Nikaida, T.; Ohmato, T. *Phytochemistry* **1992**, *31*, 3969.
- Mimaki, Y.; Kuroda, M.; Kameyama, A.; Sashida, Y.; Hirano, T.; Oka, K.; Maekawa, R.; Wada, T.; Sugita, K.; Beutler, A. J. *Bioorg. Med. Chem. Lett.* **1997**, *7*, 633.
- Deng, L.; Wu, H.; Yu, B.; Jiang, M.; Wu, J. *Chin. J. Chem.* **2004**, *22*, 994.
- (a) Guo, C.; Fuchs, P. L. *Tetrahedron Lett.* **1998**, *39*, 1099; (b) Deng, S.; Yu, B.; Hui, Y. *J. Org. Chem.* **1999**, *64*, 202; (c) Morzychi, J. W.; Gryszkiewicz, A.; Jastrzebska, I. *Tetrahedron Lett.* **2000**, *41*, 3751; (d) Yu, W.; Jin, Z. *J. Am. Chem. Soc.* **2001**, *123*, 3369; (e) Yu, W.; Jin, Z. *J. Am. Chem. Soc.* **2002**, *124*, 6576.
- (a) Marker, R. E. *J. Am. Chem. Soc.* **1940**, *62*, 3350; (b) Rosenkranz, G.; Mancera, O.; Sondheimer, F.; Djerassi, C. *J. Org. Chem.* **1956**, *21*, 520.
- (a) Tian, W. S. *Acta Chim. Sinica* **1992**, *50*, 72; (b) Tian, W. S.; Guan, H. P.; Pan, X. F. *Chin. Chem. Lett.* **1994**, *5*, 1013; (c) Tian, W. S.; Guan, H. P.; Pan, X. F. *Chin. J. Chem.* **2003**, *21*, 793; (d) Xu, Q. H.; Peng, X. W.; Tian, W. S. *Tetrahedron Lett.* **2003**, *44*, 9375; (e) Tian, W. S.; Xu, Q. H.; Chen, L.; Zhao, C. F. *Sci. China, Ser. B: Chem.* **2004**, *47*, 142; (f) Qin, H. J.; Tian, W. S.; Lin, C. W. *Tetrahedron Lett.* **2006**, *47*, 3217.
- Trost, B. M. *Acc. Chem. Res.* **2002**, *35*, 695.
- Tian, W. S.; Wang, J.; Xu, Q. H.; Lin, J. R. China Patent 200610029252.2, 2006.
- Arthur, F. K.; Michael, L. M.; Leslie, G. P. *J. Org. Chem.* **1985**, *50*, 2359.
- (a) Guo, C. X.; Fuchs, P. L. *Tetrahedron Lett.* **1998**, *39*, 1099; (b) Deng, S. J.; Yu, B.; Lou, Y.; Hui, Y. Z. *J. Org. Chem.* **1999**, *64*, 202.
- Disaccharide trichloroacetimidate **16** was synthesized according to the methods reported in Ref. 4.
- Analytical data for our synthesized 5(6)-dihydro-OSW-1 (**1**):  $[\alpha]_D^{25}$  -18.3 (c 0.38, CH<sub>3</sub>OH, lit.<sup>3</sup> -12.6 (c 0.8, CH<sub>3</sub>OH)); <sup>1</sup>H NMR (500 MHz, C<sub>5</sub>D<sub>5</sub>N):  $\delta$  8.40 (d, *J* = 8.6 Hz, 2H), 7.16 (d, *J* = 8.6 Hz, 2H), 5.76 (t, *J* = 8.2 Hz, 1H), 5.63 (t, 1H), 5.20 (d, *J* = 7.6 Hz, 1H), 4.87 (s, 1H), 4.67 (d, *J* = 6.0 Hz, 1H), 4.47 (br s, 1H), 4.32–4.22 (m, 6H), 3.83 (s, 3H), 3.25 (q, *J* = 7.6 Hz, 1H), 2.12 (s, 3H), 1.35 (d, *J* = 7.2 Hz, 3H), 1.05 (s, 3H), 0.96 (d, *J* = 7.2 Hz, 3H), 0.94 (d, *J* = 7.2 Hz, 3H), 0.91 (s, 3H). <sup>13</sup>C NMR (125 MHz, C<sub>5</sub>D<sub>5</sub>N):  $\delta$  219.05, 169.38, 165.55, 164.01, 132.54, 114.37, 114.24, 103.79, 100.95, 88.51, 85.78, 81.10, 76.46, 75.25, 72.18, 70.83, 70.76, 67.16, 55.61, 54.31, 48.27, 47.00, 46.45, 45.29, 39.44, 39.38, 37.57, 35.90, 35.64, 33.07, 32.81, 32.61, 29.22, 27.84, 22.93, 22.59, 21.01, 14.03, 12.61, 11.95; MS (ESI): 897 (M+Na<sup>+</sup>), 874 (M<sup>+</sup>).